ANI Pharmaceuticals Profit Margin

ANI Pharmaceuticals (ANIP) currently reports a profit margin of 10.16% as of March 2026. That compares with -3.12% in the prior-year period — up 425.3% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore ANI Pharmaceuticals's profit margin history and peer comparisons.

ANI Pharmaceuticals's profit margin increased from -3.12% to 10.16% — a 425.3% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ANI Pharmaceuticals's profit margin of 10.16% is lower than the Healthcare sector average of 15.29%. That is roughly 33.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but ANI Pharmaceuticals's current 10.16% should be judged against Healthcare norms (sector average: 15.29%) and against ANIP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 10.16%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for ANI Pharmaceuticals, and consider following ANIP for alerts when major investors trade the stock.